Latest news with #Julphar
Al Etihad
19-05-2025
- Business
- Al Etihad
Julphar plans to invest Dh300 million over next five years: CEO
19 May 2025 16:48 ABU DHABI (WAM) Basel Ziyadeh, CEO of Gulf Pharmaceutical Industries (Julphar), affirmed that the company continues to strengthen its position as a key driver of the pharmaceutical industry in the UAE. He noted that Julphar exports more than 80% of its production to around 40 global markets, an achievement that reflects the advancement of its manufacturing infrastructure and the efficiency of national statements to the Emirates News Agency (WAM) on the sidelines of the first day of the 'Make it in the Emirates 2025', Ziyadeh revealed an ambitious investment plan worth Dh300 million over the next five years. The plan aims to expand the manufacturing base and localise advanced technologies in cooperation with global partners, thereby supporting the national economy by boosting non-oil pharmaceutical explained that the company has invested about Dh100 million over the past three years to enhance its manufacturing infrastructure and introduce new technologies. During the same period, it launched more than 35 new pharmaceutical products, meeting the needs of the local market and exporting to various countries. He stated that after more than 45 years since Julphar's establishment, the company proudly stands as one of the first pharmaceutical firms to launch from the UAE to the world, at a time when the Arab pharmaceutical industry was almost non-existent. Today, the company exports from the UAE to dozens of global markets, relying on one of the largest industrial bases in the Arab region.
Zawya
19-05-2025
- Business
- Zawya
Julphar plans to invest $81.7mln over next five years: CEO
Basel Ziyadeh, CEO of Gulf Pharmaceutical Industries (Julphar), affirmed that the company continues to strengthen its position as a key driver of the pharmaceutical industry in the UAE. He noted that Julphar exports more than 80% of its production to around 40 global markets, an achievement that reflects the advancement of its manufacturing infrastructure and the efficiency of national talent. In statements to the Emirates News Agency (WAM) on the sidelines of the first day of the 'Make it in the Emirates' forum, Ziyadeh revealed an ambitious investment plan worth AED300 million over the next five years. The plan aims to expand the manufacturing base and localise advanced technologies in cooperation with global partners, thereby supporting the national economy by boosting non-oil pharmaceutical exports. He explained that the company has invested about AED100 million over the past three years to enhance its manufacturing infrastructure and introduce new technologies. During the same period, it launched more than 35 new pharmaceutical products, meeting the needs of the local market and exporting to various countries. He stated that after more than 45 years since Julphar's establishment, the company proudly stands as one of the first pharmaceutical firms to launch from the UAE to the world, at a time when the Arab pharmaceutical industry was almost non-existent. Today, the company exports from the UAE to dozens of global markets, relying on one of the largest industrial bases in the Arab region.
Arabian Business
16-05-2025
- Business
- Arabian Business
Julphar grows revenue 6.7% in Q1 and reduces its debts
Ras Al Khaimah-based Gulf Pharmaceutical Industries (Julphar), one of the UAE's biggest pharmaceutical companies, improved on its revenue and significantly strengthened its balance sheet by bringing down its debts in the first quarter of 2025. The company said its first quarter net revenue was AED359.2 million (US$97.8 million) showing a 6.7 per cent growth (9.6 per cent at constant rate) from AED336.8 million (US$91.7 million) and resulting in EBITDA growth from continuing operations of 9.0 per cent – from AED46.7 million (US$12.7 million) to AED50.9 million (US$13.86 million). EBITDA margin improved to 14.2 per cent, up from 13.9 per cent in the same period last year, underscoring the company's ongoing focus on operational efficiency and margin enhancement. There was a 7 per cent increase in gross profit, and it maintained a gross margin of 43 per cent. Operating income grew to AED36.3 million (US$9.9 million) as against AED30.5 million (US$8.3 million). Net income from continued operations experienced a strong improvement, reaching AED21.7 million (US$5.9 million), an increase of AED7.2 million (US$1.96 million) in the corresponding quarter in 2024. Total net profit reached AED140.9 million (US$38.4 million), driven by strong underlying performance during the period and gains from the divestment of Zahrat Al Rawdah Pharmacies LLC, its wholly owned retail pharmacy subsidiary, resulted in a one-time capital gain of AED118.7 million (US$32.3 million). Reduced debt Julphar's total bank borrowings reduced by AED383.2 million (US$104.34 million), bringing its total interest-bearing liabilities to AED529.9 million (US$144.3 million). Total equity increased to AED948.7 million (US$258.3 million), up from AED809.6 million (US$220.45 million) at the end of 2024, reducing accumulated losses from AED305 million (US$83 million) to AED164.1 million (US$44.68 million). The company also improved its product mix, launching five new products, including three insulin analogues in UAE. It also secured 11 new regulatory approvals across regional markets. Julphar entered into an exclusive licensing agreement with Dong-A ST, one of South Korea's most reputable pharmaceutical companies, to introduce Darbepoetin biosimilar in the MENA region. Darbepoetin Alfa is a medication that helps the body produce more red blood cells to treat anaemia caused by kidney failure or chemotherapy. Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, commented: 'Serving millions of patients across therapeutic areas, we are confident that our growth mindset and focus on innovation, collaboration and geographical expansion will help us deliver continued positive impact to the healthcare sector and to the knowledge economy in the GCC and beyond. 'Our Growth Strategy 2030 guides our commitment to deliver excellence in the form of first-to-market products and value-adding medicines.' The company said it remains focused on accelerating its growth strategy by expanding its footprint in core markets and fostering innovation through continued investment in high-value, differentiated products while maintaining financial discipline and a strong capital structure. Basel Ziyadeh, Chief Executive Officer, Julphar, added: 'We are entering a phase of accelerated growth, driven by disciplined execution and an unwavering commitment to innovation. Our focus is on becoming a more agile and efficient organisation while solidifying the foundation for sustained, long-term growth. 'With clear strategic priorities, we are taking decisive actions to create long-term value and establish market leadership. This includes significant investments in our manufacturing facilities in the UAE in addition to our recently announced investment in Saudi Arabia, and in a strong R&D pipeline.'
Zawya
04-05-2025
- Health
- Zawya
EDE strengthens partnerships to ensure pharmaceutical security and support industry growth
Dr. Thani Al Zeyoudi: 'We are striving to achieve strategic integration among stakeholders in the pharmaceutical sector, which is the backbone of our national health security strategy.' Dr. Fatima Al Kaabi: 'We are committed to investing in innovation and technology to build a fully integrated pharmaceutical ecosystem that can meet future demands.' Dr. Al Zeyoudi and EDE members briefed on the latest technologies being utilized in pharmaceutical manufacturing Commending national companies' contributions to 'Make it in the Emirates' initiative and economic growth Exploring avenues for supporting the pharmaceutical sector and enhancing long-term self-sufficiency UAE, Ras Al Khaimah: His Excellency Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade and Chairman of the Board of Directors of the Emirates Drug Establishment (EDE) visited the Gulf Pharmaceutical Industries (Julphar) in Ras Al Khaimah. His Excellency was accompanied by H.E. Dr. Maha Taysir Barakat, Assistant Minister for Medical Affairs and Life Sciences Ministry of Foreign Affairs, as the Vice Chairman of EDE, H.E. Dr. Amer Ahmad Sharif, CEO of Dubai Academic Health Corporation and President of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and Member of the EDE Board of Directors, H.E. Dr. Fatima Al Kaabi, Director General of EDE, and Ahmed Al Rumaithi, Youth representative on the EDE Board of Directors. During the visit, H.E. Al Zeyoudi along with board members toured Julphar's production facilities, where they were briefed about the company's advanced manufacturing lines and technologies used to produce a wide range of pharmaceutical products, including treatments enhancing patients' quality of life. The visit comes as part of the establishment's commitment to empowering national pharmaceutical manufacturers and strengthening the UAE's pharmaceutical security system. It also aligns with the EDE's objectives to build effective partnerships with local producers, enhance domestic manufacturing capacity, and promote self-sufficiency, reinforcing the UAE's position as a regional and global hub for innovative pharmaceutical development. World-class pharmaceutical ecosystem His Excellency Dr. Thani Al Zeyoudi emphasised that the pharmaceutical sector plays a fundamental role in building a strong, integrated healthcare system in the UAE, commending Julphar for its remarkable achievements and positioning as a leading national example in the industry. He expressed his appreciation for the company's contributions, describing Julphar as one of the UAE's prestigious institutions in the pharmaceutical field. Al Zeyoudi reaffirmed the establishment's keenness to support successful homegrown industrial projects that contribute to realising the country's goals of developing a diversified and sustainable economy. His Excellency also lauded the important role that national companies play in driving the success of the 'Make it in the Emirates' initiative, which is designed to showcase the strength of local products and enhance their competitiveness in international markets. 'Through these visits, we seek to build a strategic collaboration among key players in the pharmaceutical sector,' the minister said. 'Promoting locally manufactured pharmaceutical products is not only a priority within our national health security strategy but also reinforces the leadership's vision to diversify the economic base and institutionalise sustainability and competitiveness across strategic industries.' His Excellency added: 'The establishment has adopted an integrated approach that focuses on strengthening regulatory frameworks, delivering technical support to local manufacturers, driving investment in research and development, and opening new avenues for scientific collaboration with international institutions. Our efforts are all directed toward a single goal: to ensure the availability of safe and effective pharmaceutical products at competitive prices and to develop a national pharmaceutical industry that competes effectively on the global stage.' Empowering national capabilities For her part, Dr. Fatima Al Kaabi stressed that the establishment is committed to strengthening collaboration with national manufacturers such as Julphar, recognising its role as a key partner in advancing the UAE's pharmaceutical security goals. 'Our future plans are not only aimed at enhancing organisational efficiency, and building advanced technological platforms, but also at forging effective partnerships to support the growth and expansion of local pharmaceutical manufacturers,' Al Kaabi said. 'We are also working to adopt world-class pharmaceutical control and quality assurance systems in line with international best practices.' She added: 'We are continuously exploring the use of artificial intelligence to upgrade pharmaceutical research and production while encouraging local companies to expand their export footprint. At the same time, we are keen to build global partnerships that facilitate the transfer of advanced knowledge and expertise to national talent across this vital sector.' EDE Support Meanwhile, Basil Ziadeh, CEO of Julphar, expressed his appreciation for the visit, highlighting its importance in strengthening cooperation between the public and private sectors. 'We are honoured by the visit of His Excellency Dr. Thani Al Zeyoudi and his delegation. This reflects the government's continued support for the pharmaceutical sector. 'At Julphar, we are committed to utilising the latest innovations, investing in national talent, and adopting modern technologies. We will continue to support the country's strategic goals of achieving pharmaceutical self-sufficiency and bolstering the UAE's position as a leading regional manufacturing hub. Make it in the Emirates initiative is truly a source of pride and it will continue to be our guiding light as we pursue sustainable growth and global competitiveness.' The company also expressed its appreciation for the Emirates Drug Establishment's initiative to fast-track the evaluation of national manufacturers' products. This initiative, which includes an integrated and expedited mechanism supported by a wide range of incentives and competitive advantages, will significantly boost the national pharmaceutical industry. It will also enhance its capacity to compete in international markets. The visit featured an interactive dialogue session that explored challenges and opportunities within the pharmaceutical sector. Discussions focused on strengthening public-private sector coordination, enhancing the legislative and regulatory environment, promoting investment in research and development, and supporting innovation initiatives aligned with national strategic objectives.
Zawya
01-05-2025
- Business
- Zawya
Global manufacturing portfolio leads innovation at AIM Congress 2025
Abu Dhabi, UAE: The Global Manufacturing portfolio at AIM Congress 2025 concluded with outstanding success, reinforcing its vital role in shaping the future of smart manufacturing under the theme: ' From Industry 4.0 to 5.0: Leveraging Technology & Advancing Smart Factories.' The portfolio delivered deep insights into the transformation of manufacturing ecosystems, product innovation, operational efficiency, and sustainability. Discussions highlighted the industry's commitment to minimizing manual processes, optimizing resource utilization, ensuring worker safety, and boosting productivity and competitiveness. A standout highlight of the portfolio was the focus on the pharmaceutical industry as a pioneering force of innovation. By embracing smart manufacturing, data analytics, automation, and technologies from the Fifth Industrial Revolution, pharmaceutical companies are accelerating research and development, improving product quality, reducing waste, and meeting the growing demand for affordable, sustainable medicines. Moreover, advanced technologies like artificial intelligence and the Internet of Things have proven essential in enhancing supply chain resilience and global health security, ensuring rapid and efficient responses to future health challenges. The tremendous success of the Global Manufacturing portfolio was made possible thanks to the invaluable support of our esteemed partners: Julphar (Lead Partner), Modern Pharmacy (Diamond Partner), Global Pharma LLC (Diamond Package), Quest Vitamin Middle East (Associate Partner), MSD (Silver Partner), Life Pharma (Gold partner package), ADMD (Silver Partner), Vieco (Silver Partner), J&J (, Novartis (Diamond Partner), Biogen (Associate Partner), Servier (Silver Partner), Tabuk Pharmaceuticals (Associate Partner), City Pharmacy (Silver Partner), Gulf Drug (Silver Partner), Hikma (Silver Partner), Safe care/Pure Pharma(Silver Partner), and PHRMAG (Round Table partner). showcased their latest innovations and advanced technological solutions in smart manufacturing, automation, and data analytics. Their booths witnessed significant visitor engagement, with attendees showing great interest in the displayed technologies, reflecting the vital role these companies play in driving innovation and promoting sustainability in the pharmaceutical industry. The support of these partners has embodied a true model of collaboration and innovation, reinforcing the position of the Global Manufacturing Hub as a pioneering platform for advancing digital transformation and promoting sustainable practices in the pharmaceutical industry within the United Arab Emirates. These active partnerships have contributed to accelerating the development of the industrial sector, while emphasizing the critical role of the pharmaceutical industry in supporting national economies and strengthening global health security. In this context, the pivotal role of the Emirates Drug Establishment (EDE) has emerged clearly, as it coordinated efforts among stakeholders and supported initiatives aimed at developing the regulatory and legislative infrastructure — positioning the UAE as a regional hub for pharmaceutical manufacturing. This strategic collaboration also marked an important step toward growing the pharmaceutical sector and creating an investment-friendly local environment that fosters advanced solutions to enhance quality of life. AIM Congress 2025 looks forward to building on this success, continuing to drive the global conversation on industrial innovation, sustainability, and resilience for years to come.
